Eating Disorders & Weight Management News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Mounjaro Beats Ozempic in Real-World Study
A new study of real-world health records adds to the evidence that Eli Lilly’s obesity shot is a more effective weight loss treatment than Novo Nordisk’s.#elilillys #novonordisks (Source: Reuters: Health)
Source: Reuters: Health - November 28, 2023 Category: Consumer Health News Source Type: news

Mounjaro 3 times more effective than Ozempic for weight loss, study finds
Eli Lilly’s Mounjaro is significantly more effective than Novo Nordisk’s Ozempic in producing weight loss in patients with overweight or obesity, a new real-world study found. In an analysis of 18,000 patients, those taking Mounjaro were three times more likely than those taking Ozempic to achieve…#elilillysmounjaro #novonordisksozempic #mounjaro #truvetaresearch (Source: Reuters: Health)
Source: Reuters: Health - November 27, 2023 Category: Consumer Health News Source Type: news

How To Earn $500 A Month From Pfizer Stock
Shares of Pfizer Inc. are hovering around $30 as investors adjust to the company's pursuit of a candidate for a weight loss pill, marking its entry into the competitive obesity drug market. The Street responded critically. JPMorgan Chase & Co analysts called the news a setback for the company.…#pfizerinc #jpmorganchaseco #svbsecurities #yahoo #pfizer #nonejeffbezos #nonereal #jeffbezos #nonepassive #benzingaproclick (Source: Reuters: Health)
Source: Reuters: Health - November 27, 2023 Category: Consumer Health News Source Type: news

Mounjaro vs Ozempic for Obesity; New Microwave Ablation System; GAHT Erythrocytosis
(MedPage Today) -- A real-world, preprint study in medRxiv found that people with overweight or obesity were up to three times more likely to lose significant weight with tirzepatide (Mounjaro) than with semaglutide (Ozempic), though the study... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - November 27, 2023 Category: Endocrinology Source Type: news

PROFESSOR ROB GALLOWAY: I thought I didn't have to worry about my weight since I'm 'fat but fit'... I was wrong
PROFESSOR ROB GALLOWAY: The latest figures from the Health Survey for England found that 25.9 per cent of adults are obese and a further 37.9 per cent are overweight but not obese. (Source: the Mail online | Health)
Source: the Mail online | Health - November 27, 2023 Category: Consumer Health News Source Type: news

Bariatric Surgery Still Best Option for Some With Obesity Bariatric Surgery Still Best Option for Some With Obesity
Despite the rapid emergence of glucagonlike peptide-1 agonists for treating obesity, bariatric surgery may still be a better choice for some individuals, two experts say.Endocrine Society (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - November 27, 2023 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Wegovy-maker Novo Nordisk could make prices flexible —without cutting them
Novo Nordisk’s sales have skyrocketed with the popularity of its weight-loss and obesity drugs. The Danish drugmaker’s sales in those two categories were up 36% in the nine months of 2023, to $22 billion. But as demand has outstripped supply, with millions of possible patients yet to be served,…#novonordisks #danish #novo #norway #denmark #fortune #elililly #lilly #mounjaro #wegovy (Source: Reuters: Health)
Source: Reuters: Health - November 27, 2023 Category: Consumer Health News Source Type: news

Breaking the cycle: identifying key symptom pathways of eating disorders and the influence of childhood maltreatment - Kopland MCG, Vrabel KA, Slof-Op 't Landt M, Hoffart A, Johnson SU, Giltay EJ.
BACKGROUND: Most network analyses on central symptoms in eating disorders (EDs) have been cross-sectional. Longitudinal within-person analyses of therapy processes are scarce. Our aim was to investigate central change processes in therapy in a transdiagnos... (Source: SafetyLit)
Source: SafetyLit - November 27, 2023 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

Novo Nordisk looks at flexible pricing for obesity drug
Danish pharma group in talks with healthcare providers about innovative models to boost Wegovy take-up (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - November 27, 2023 Category: Pharmaceuticals Source Type: news

Five hundred new jobs coming in Chartres, south of Paris
On Thursday, Danish pharmaceutical giant Novo Nordisk announced a major investment in a French production site to expand the capacity and manufacturing of a blockbuster anti-obesity drug. On Thursday, Danish pharmaceutical giant Novo Nordisk announced a major investment in a French production site…#danish #novonordisk #emmanuelmacron #chartres #semaglutide #marketed #denmark #norway #goldmansachs #goldman (Source: Reuters: Health)
Source: Reuters: Health - November 26, 2023 Category: Consumer Health News Source Type: news

Denmark's Novo Nordisk invests €2.1 billion in France
Danish pharmaceutical giant Novo Nordisk has announced major investment in a French production site to expand the capacity and manufacturing of its blockbuster anti-obesity drug. In a landmark move, Danish pharmaceutical giant Novo Nordisk is set to inject a substantial €2.1 billion into its…#danish #novonordisk #chartres #emmanuelmacron #denmark #norway #goldmansachs #elililly #charlottelarsen (Source: Reuters: Health)
Source: Reuters: Health - November 24, 2023 Category: Consumer Health News Source Type: news

Novo Nordisk's Wegovy Eyes Asian Market Debut Despite Supply Crunch
Novo Nordisk A/S NVO reportedly plans to introduce its highly sought-after anti-obesity medication, Wegovy, in Japan on February 22, marking its inaugural entry into the Asian market despite facing supply/demand challenges. Japan, chosen as the sixth country for Wegovy's launch, presents a…#novonordiskasnvo #wegovy #novo #novonordisk #bmi #chartres #glp1 #ozempic #kalundborg #denmark (Source: Reuters: Health)
Source: Reuters: Health - November 24, 2023 Category: Consumer Health News Source Type: news

Ozempic maker plans manufacturing blitz as market for the drug is expected to top $100 billion in 2030
Novo Nordisk makes Ozempic and Wegovy, two hit drugs that treat obesity. • Supply is a major issue right now, with the firm warning a European regulator it may ration Ozempic. • In the past two weeks, it's announced more than $8 billion in manufacturing investments. Novo Nordisk, maker of the…#novonordisk #ozempicandwegovy #supply #emmanuelmacron #novo #chartres #denmark #ozempic #elililly #davidricks (Source: Reuters: Health)
Source: Reuters: Health - November 24, 2023 Category: Consumer Health News Source Type: news

Wegovy-Maker Novo Nordisk to Spend More Than $2 Billion Boosting Production in France
Pharmaceutical giant Novo Nordisk said it will invest more than 16 billion Danish kroner ($2.34 billion) in its French production site as it seeks to meet rising demand for its blockbuster obesity and diabetes treatments. The Danish company, which makes the Wegovy obesity drug and diabetes drug…#novonordisk #danish #chartres (Source: Reuters: Health)
Source: Reuters: Health - November 24, 2023 Category: Consumer Health News Source Type: news

Ozempic maker plans manufacturing blitz as market for the drug is expected to top $100 billion in 2030
Getty Images Novo Nordisk makes Ozempic and Wegovy, two hit drugs that treat obesity. Supply is a major issue right now, with the firm warning a European regulator it may ration Ozempic. In the past two weeks, it's announced more than $8 billion in manufacturing investments. Novo Nordisk, maker of…#novonordisk #ozempicandwegovy #emmanuelmacron #novo #chartres #denmark #ozempic #elililly #davidricks #lilly (Source: Reuters: Health)
Source: Reuters: Health - November 23, 2023 Category: Consumer Health News Source Type: news